NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
NEW YORK, NY / ACCESS Newswire / April 4, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors ...
Intellia doses first subject in trial of nex-z for hereditary ATTRv-PN
The trial is structured to assess the safety and efficacy of the therapy in approximately 50 ATTRv-PN subjects.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Acquired by Mitsubishi UFJ Asset Management Co. Ltd.
Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by ...
Le Lézard17h
NTLA Investors Have Opportunity to Lead Intellia Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Intellia Therapeutics, Inc. ("Intellia" or the "Company") and reminds investors of the April 14, ...
Levi & Korsinsky Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – NTLA
NEW YORK, NY / ACCESS Newswire / April 3, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to ...
The Manila Times19h
Mulvihill Premium Yield Fund Declares Monthly Fund Distribution for Its ETF Class
TORONTO, April 03, 2025 (GLOBE NEWSWIRE) -- (TSX: MPY) Mulvihill Premium Yield Fund has declared a monthly cash distribution for its ETF Class in the amount of $0.06400 per unit, payable on May 7, ...
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...
7 Top Gene-Editing Stocks to Buy
Analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $40.1 billion by 2034, ...
Le Lézard20h
NTLA Deadline: NTLA Investors with Losses in Excess of $100K Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit
Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therapeutics, Inc. between July 30, 2024 and January 8, 2025, both dates inclusive (the "Class Period"), ...